Rheumatoid Arthritis
Strong data supports the development of MBV-based therapeutic strategies that direct endogenous immune cells to orchestrate immunomodulation and constructive remodeling for a broad array of autoimmune-driven pathologies.
Strong data supports the development of MBV-based therapeutic strategies that direct endogenous immune cells to orchestrate immunomodulation and constructive remodeling for a broad array of autoimmune-driven pathologies.
The findings of our recent preclinical study published in Nature Regenerative Medicine show that the immunomodulatory properties of MBV have therapeutic potential for diseases driven by a dysregulated immune system such as Rheumatoid Arthritis (RA). The study results show that both systemic and local administration of ECM-derived MBV are equally effective as methotrexate (MTX) in mitigating acute and chronic pristane-induced RA in the rat.
Although MBV and Methotrexate treatments reduced synovial inflammation, cartilage destruction, and pro-inflammatory synovial and systemic macrophage phenotype, only the MBV treatment decreased clinically relevant pro-inflammatory serum chemokines and promoted a systemic myeloid shift towards an anti-inflammatory and immunoregulatory phenotype. Stated differently, MBV treatment had a distinctive and favorable immunomodulatory effect that differed from that of immunosuppressive MTX treatment.
A regenerative medicine company utilizing naturally occurring extracellular matrix based signaling molecules to treat unmet medical needs.
118 Marshall Drive
Warrendale, PA 15086
(814) 325-2328
info@ecmtherapeutics.com